Teva's UZEDY Cuts Schizophrenia ER Visits and Saves $1,000+ Per Patient Monthly in New Data

The Quick Take

• New real-world data show UZEDY (risperidone) outperforms rival long-acting injectables in treatment continuity
• UZEDY reduced emergency room visits and hospitalizations versus oral antipsychotics in bipolar I disorder
• Patients on UZEDY generated over $1,000 per patient per month in direct healthcare cost savings
• Teva is leveraging UZEDY's pharmacoeconomic profile to accelerate formulary placement in North American markets

Synthesized from 1 source — full coverage, sentiment breakdown, and forward signals below.

Teva Pharmaceuticals presented compelling new real-world evidence showing that UZEDY (risperidone)—its subcutaneous long-acting injectable—demonstrated superior treatment continuity versus competing long-acting injectables for schizophrenia. The data also showed favorable outcomes for bipolar I disorder patients when compared against oral antipsychotics, extending UZEDY's evidence base beyond its primary schizophrenia indication. Emergency room visits and hospitalizations were meaningfully lower for UZEDY patients, translating into more than $1,000 per patient per month in direct healthcare resource savings—a compelling pharmacoeconomic argument for payers and hospital formulary committees. The findings position UZEDY strategically ahead of anticipated formulary review cycles at major US and Canadian health systems in Q4 2026.

Teva, which has been rebuilding its specialty pharma portfolio after years of generic litigation headwinds, is banking on UZEDY's combined clinical and pharmacoeconomic profile to drive commercial acceleration in psychiatry. With schizophrenia representing a $7+ billion US market, even marginal formulary share gains from payer-aligned evidence carry meaningful revenue upside for Teva's psychiatry franchise. The real-world data cover both treatment adherence and cost outcomes—two dimensions that directly influence managed care contracting decisions and preferred tier placement. Competing LAI manufacturers including J&J and AbbVie will need to respond with their own pharmacoeconomic data to defend formulary positions against UZEDY's growing evidence package.